Ceftazidime sodium - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ceftazidime sodium and what is the scope of patent protection?
Ceftazidime sodium
is the generic ingredient in two branded drugs marketed by Baxter Hlthcare and Pai Holdings Pharm, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.Summary for ceftazidime sodium
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 14 |
Clinical Trials: | 5 |
Patent Applications: | 56 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ceftazidime sodium at DailyMed |
Recent Clinical Trials for ceftazidime sodium
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Arrevus Inc. | Phase 2 |
Zunyi Medical College | N/A |
Federal University of São Paulo | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for ceftazidime sodium
US Patents and Regulatory Information for ceftazidime sodium
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baxter Hlthcare | CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | ceftazidime sodium | INJECTABLE;INJECTION | 063221-002 | Apr 29, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Pai Holdings Pharm | FORTAZ IN PLASTIC CONTAINER | ceftazidime sodium | INJECTABLE;INJECTION | 050634-001 | Apr 28, 1989 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Baxter Hlthcare | CEFTAZIDIME SODIUM IN PLASTIC CONTAINER | ceftazidime sodium | INJECTABLE;INJECTION | 063221-001 | Apr 29, 1993 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |